Key result
Catecholamine-secreting tumors linked to higher plasma ANF levels versus age-matched controls.
Why the study?
The relationship between plasma atrial natriuretic factor levels and catecholamine secretion in patients with catecholamine-producing tumors was unclear.
Are plasma ANF levels increased in patients with catecholamine-producing tumors compared to controls?
Case-Control (n=55)
Are plasma ANF levels increased in patients with catecholamine-producing tumors compared to controls?
Answers are grounded in this paper and cite their sources.
Plasma ANF is elevated in patients with catecholamine-secreting tumors, but this increase does not appear to be directly driven by excessive catecholamine secretion.
The aim of this study was to evaluate plasma levels of ANF in patients with catecholamine-secreting tumors with and without hypertension and to relate ANF secretion to levels of plasma and urinary catecholamines and blood pressure. Twenty-one pheochromocytoma (15 with sustained, 6 with paroxysmal hypertension), 6 neuroblastoma (1 hypertensive) patients and 28 aged-matched controls were studied in basal conditions. Plasma and urinary norepinephrine (NE),epinephrine (E), dopamine (DA) and DOPA were determined by HPLC-ED and plasma ANF by RIA. Both neuroblastoma and pheochromocytoma patients had significantly higher plasma ANF levels than controls. Neuroblastomas showed higher ANF concentration than pheochromocytomas. No differences were found in plasma ANF between hypertensive and normotensive patients. Pheochromocytomas with ANF levels within the normal range had plasma and urinary NE and urinary DA and DOPA levels significantly higher than patients with high ANF. Plasma ANF levels were unrelated to systolic or diastolic blood pressure or heart rate. A negative correlation between plasma ANF and urinary DA was found only in the patients groups. In conclusion, plasma ANF was increased in pheochromocytoma and neuroblastoma patients. Our data suggest that the excessive catecholamine secretion is not responsible for the increased ANF secretion in these patients. The significance of the relationships among plasma ANF and urinary and plasma catecholamines requires further investigation.
No takes yet. Share an insight, caveat, or question.
Puyó et al. (1999) conducted a case-control in Catecholamine-secreting tumors (n=55). Catecholamine-secreting tumors vs. Age-matched controls was evaluated on Plasma ANF levels. Patients with catecholamine-secreting tumors (pheochromocytoma and neuroblastoma) had significantly higher plasma ANF levels than age-matched controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: